Norelgestromin And Ethinyl Estradiol Patch
Product Images NDC 70710-1190

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Norelgestromin And Ethinyl Estradiol (NDC 70710-1190). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2.3 (404277f1 4343 462c B508 10c22dc7bc2c 01)

Instructional images showing the application sites for the norelgestromin and ethinyl estradiol transdermal patch on a female body. The patch is shown applied on the upper outer arm, lower abdomen, buttock, and upper back, demonstrating proper placement options.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 52 2)

The image shows a transdermal patch for norelgestromin and ethinyl estradiol, human prescription drug by Zydus Pharmaceuticals USA Inc. The patch is sealed within a clear, square, foil-lined pouch held by a gloved hand. No specific strength or detailed labeling is visible on the patch or packaging.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 52 3)

An instructional illustration showing hands applying a norelgestromin and ethinyl estradiol transdermal patch to the skin. The image demonstrates proper handling and placement of the contraceptive patch.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 52 4)

An instructional black-and-white image showing the application of a transdermal patch on the lower abdomen. A person's hands are applying a square patch to the skin, demonstrating proper placement and adhesion technique.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 52 5)

An illustration showing hands applying a norelgestromin and ethinyl estradiol transdermal patch to the lower abdomen. The patch is rectangular and visibly centered on the skin, demonstrating correct placement for this hormonal contraceptive method.*

FDA Label Image

Figure2 (404277f1 4343 462c B508 10c22dc7bc2c 02)

A horizontal bar chart showing the number of women with a blood clot per 10,000 woman-years (WY) across four different groups: Non-CHC user/non-pregnant ranging 1 to 5, CHC user ranging 3 to 12, pregnancy ranging 5 to 20, and postpartum (12 weeks only) ranging 40 to 65. The chart includes footnotes explaining CHC as combination hormonal contraception and pregnancy data assumptions.*

FDA Label Image

Figure-2 (404277f1 4343 462c B508 10c22dc7bc2c 03)

A forest plot chart depicting effect estimates (Odds Ratio/Relative Risk) with confidence intervals for various studies related to contraceptive use from 2002 to 2017. The x-axis ranges from -1.5 to 2 for effect estimates, showing points and error bars for each study's results comparing 'Ever Use' and 'Current Use' groups.*

FDA Label Image

Structure (404277f1 4343 462c B508 10c22dc7bc2c 04)

Chemical structure diagrams of the active ingredients norelgestromin and ethinyl estradiol, shown side by side with labeled molecular structures. These are components of the transdermal patch product by Zydus Pharmaceuticals USA Inc.*

FDA Label Image

Figure3 (404277f1 4343 462c B508 10c22dc7bc2c 05)

A pharmacokinetic line graph showing the concentration of norelgestromin (NGMN) in ng/mL over time in hours (0 to 240). The graph compares NGMN concentration profiles for Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3, illustrating changes in drug levels across these time points during transdermal patch administration.*

FDA Label Image

Figure4 (404277f1 4343 462c B508 10c22dc7bc2c 06)

A line graph depicting ethinyl estradiol (EE) concentration in pg/mL over time in hours (0 to 240). It compares EE levels at different weeks and cycles, showing curves for Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3, with concentrations rising initially and varying across time points before dropping near 168 hours.*

FDA Label Image

Figure5 (404277f1 4343 462c B508 10c22dc7bc2c 07)

A line chart comparing NGMN (norelgestromin) concentration in ng/mL over time in hours for a transdermal system applied to the buttock and oral contraceptives. The graph shows steady concentration levels for the transdermal system up to 144 hours and multiple peaks for oral contraceptives within 240 hours, including estimated steady state data based on day 21.*

FDA Label Image

Figure6 (404277f1 4343 462c B508 10c22dc7bc2c 08)

A line graph showing serum ethinyl estradiol (EE) concentration (pg/mL) over time (hours) comparing norelgestromin and ethinyl estradiol transdermal system applied to the buttock versus oral contraceptive (NGM 250 μg/EE 35 μg). The graph includes steady-state data estimates for the oral contraceptive based on day 21. The transdermal system shows a more stable EE concentration over time compared to oral administration.*

FDA Label Image

Image (404277f1 4343 462c B508 10c22dc7bc2c 244 1)

Chart showing effectiveness of various birth control methods based on pregnancies per 100 women per year. Methods causing fewer pregnancies include implants, injections, intrauterine devices, and sterilization. Moderate effectiveness methods include birth control pills, skin patch, and vaginal rings with hormones. Less effective methods include condoms and diaphragm. Least effective methods listed are abstinence during fertile days, spermicide, withdrawal, and no birth control.*

FDA Label Image

Image (404277f1 4343 462c B508 10c22dc7bc2c 244 2)

A weekly calendar diagram illustrating a 4-week schedule for norelgestromin and ethinyl estradiol transdermal patches. Days 1 to 21 (three weeks) have shaded bars indicating patch application, while Week 4 is labeled "NO PATCH," instructing no patch use during this period.*

FDA Label Image

Image (404277f1 4343 462c B508 10c22dc7bc2c 244 3)

A horizontal bar chart depicting the number of women with a blood clot per 10,000 woman-years (WY) across four groups: Non-CHC user non-pregnant, CHC user, Pregnancy, and Postpartum (12 weeks only). Each group shows a range of risk values, with postpartum having the highest range from 40 to 65, followed by pregnancy 5 to 20, CHC user 3 to 12, and non-CHC user non-pregnant 1 to 5. Notes clarify CHC as combination hormonal contraception and define pregnancy data assumptions.*

FDA Label Image

Ifu-1 (404277f1 4343 462c B508 10c22dc7bc2c 09)

An instructional image labeled 'Figure A' showing gloved hands holding a transdermal patch next to its partially opened foil pouch, illustrating how to remove the patch from the packaging.*

FDA Label Image

Ifu-2 (404277f1 4343 462c B508 10c22dc7bc2c 10)

An illustration showing a hand holding a small rectangular transdermal patch. This image likely demonstrates the size or handling of the norelgestromin and ethinyl estradiol transdermal patch product by Zydus Pharmaceuticals USA Inc.*

FDA Label Image

Ifu-3 (404277f1 4343 462c B508 10c22dc7bc2c 11)

Illustrations show the proper application sites for the norelgestromin and ethinyl estradiol transdermal patch on a woman's body, including the upper arm, lower abdomen, buttocks, and upper back near the shoulder blade.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 232 2)

A clear protective pouch held in a gloved hand, containing a norelgestromin and ethinyl estradiol transdermal patch. The pouch is square and transparent, showing the rectangular medication patch inside. No printed text or labeling is visible on the pouch in the image.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 232 3)

An instructional illustration showing two hands peeling a protective backing off a transdermal patch. The image demonstrates the step of preparing the patch for application on the skin.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 232 4)

An instructional illustration showing a person applying a rectangular transdermal patch onto the skin just below the navel on the abdomen. The image demonstrates the placement and application technique of a norelgestromin and ethinyl estradiol contraceptive patch.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 232 5)

An illustration showing a person applying a rectangular transdermal patch to the lower abdominal skin. The patch is white and has rounded corners. The image demonstrates the correct placement of the patch on the body.*

FDA Label Image

Carton (404277f1 4343 462c B508 10c22dc7bc2c 12)

Packaging label for Norelgestromin and Ethinyl Estradiol Transdermal System 150/35 mcg per day patch by Zydus Pharmaceuticals USA Inc. The label includes dosage strength, usage instructions, storage conditions, and manufacturer details. It indicates the product contains 3 transdermal systems and is for prescription use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.